Vice President of Product Management

Medline neurosurgical sponge recall: A Staritas resource to support informed substitution decisions. On March 13, 2026, Medline announced a voluntary recall of its neurosurgical sponges due to elevated endotoxin levels. All affected products must be destroyed, and there is currently no timeline for return, creating an immediate supply disruption for providers that rely on these sponges for critical procedures. Neurosurgical sponges are essential in delicate operations where sterility, precision, and absorbency are non-negotiable. This recall presents more than a sourcing challenge. Clinical teams must rapidly evaluate alternatives, supply chain leaders must secure inventory in a constrained market, and finance teams must manage pricing volatility, all while ensuring continuity of care. To support providers navigating this disruption, Staritas has developed a Functional Equivalence Report identifying U.S. alternatives to the recalled Medline products. The report goes beyond a substitute list by offering structured comparisons across key clinical specifications such as size, materials, absorbency, and intended use. This approach helps teams assess safety and performance with confidence. The report also includes Supply Guide price benchmarks, giving supply chain and finance leaders critical visibility into market pricing at a time when demand shifts and cost pressures are high. Together, these insights empower faster, more informed decision-making, strengthen cross-functional alignment, and help make every choice clear. While recalls are disruptive, they also underscore the importance of preparedness, including clear cross-department communication, supplier diversification, and data-driven inventory management. With the right tools and insight, organizations can respond strategically rather than reactively. Staritas partners with healthcare organizations to navigate disruptions like this one by turning uncertainty into informed action and helping ensure patient care continues without compromise. Explore how Staritas Functional Equivalents and Recall Management solutions can help you quickly identify appropriate alternatives, assess risk exposure, and respond to disruptions with clarity and confidence.

Medline receives FDA warning letter on its heart procedure syringes. April 09, 2026 01:29 PM CDT The Food and Drug Administration has sent a warning letter to Medline Industries over reported issues with syringes used in cardiac procedures and the company could face regulatory action if the issues are not corrected. Staying current is easy with newsletters delivered straight to your inbox.

FDA flags quality system lapses at Medline facility over device risks. Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. The U.S. Food and Drug Administration has issued a warning letter to Medline Inc. (NASDAQ:MDLN), following an inspection that identified significant quality system violations tied to its cardiovascular device kits, raising concerns about patient safety and regulatory compliance. FDA flags manufacturing and quality system failures. The inspection, conducted between December 1 and December 12, 2025, at Medline's New York facility, found that the company's angiographic control syringes and related components failed to meet current good manufacturing practice standards. The FDA determined the devices were "adulterated" under federal law due to deficiencies in manufacturing controls, quality systems, and compliance with established regulations. CAPA process breakdown raises safety concerns. The letter dated March 25 highlighted Medline's failure to properly implement corrective and preventive action (CAPA) procedures. Despite 221 complaints and 177 medical device reports tied to syringe disconnections, the company's corrective actions - such as scrapping inventory and increasing cleaning frequency - were deemed insufficient relative to the risk. The FDA noted inconsistencies in Medline's risk assessments, particularly where internal analyses flagged severe risks like air embolism, while the company classified the overall risk as low. Complaint trends also remained above established thresholds even after corrective actions were introduced, yet the company did not escalate or reopen investigations as required. Device recall and ongoing investigations. Medline acknowledged the shortcomings, closed the initial CAPA, and initiated new investigations alongside a product removal plan. The company submitted a formal report to the FDA in March 2026 outlining the removal of affected devices. However, regulators flagged gaps in the scope and timeline of these actions, including unclear investigation deadlines and inconsistencies in manufacturing data tied to complaint rates. Medline contamination risks and cleaning deficiencies. The FDA also cited failures in maintaining cleanroom standards, with visible particulate matter found on manufacturing equipment. More than 100 complaints related to foreign material contamination were recorded over two years. While Medline implemented corrective cleaning measures and updated procedures, the FDA said the company did not adequately assess the impact on products already in the market. Further violations involved inadequate design verification processes. The FDA found insufficient documentation supporting testing decisions for device components, raising questions about whether all affected products met required standards. Regulatory risks and next steps. The FDA warned that failure to address these issues could lead to enforcement actions, including fines or product seizures. Medline has been directed to submit a detailed remediation plan within 15 business days and align all corrective actions with updated Quality Management System Regulation requirements that took effect in February 2026. In February, Medline identified electrical safety risks with its Medline Basic Homecare Beds that may lead to fire. MDLN Price Action: Medline shares were up 2.93% at $45.64 at the time of publication on Thursday, according to Benzinga Pro data. Everyone Bought NVIDIA. The Smart Money Is Now Buying What NVIDIA Needs to Run. The chip trade is crowded. Valuations are stretched. The investors who made money on Phase 1 of AI are already repositioning into the one thing every data center depends on: uninterrupted power. Natural gas and nuclear are the only sources that can deliver it at scale - and one small company just landed a deal to power multiple new hyperscale data centers. Posted In: